Shahid Nimjee
Chief Medical Officer
Basking Biosciences
Basking Biosciences is developing BB-031, a reversible RNA aptamer designed to target von Willebrand Factor for the treatment of acute ischemic stroke. This therapy aims to provide a rapid-onset, short-acting solution for reopening blocked arteries while allowing for quick neutralization in case of bleeding complications.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$62.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current treatments for acute ischemic stroke (AIS) have limitations, including a narrow therapeutic window and risks of intracerebral hemorrhage, leaving a significant portion of patients without effective options for restoring blood flow to the brain. Device-based endovascular thrombectomy is limited by its ability to retrieve clots only in large vessels and is unavailable in many acute care centers. The majority of AIS patients do not receive acute treatment, leading to increased mortality and disability.
Solution
Basking Biosciences is developing BB-031, a reversible RNA aptamer designed to target von Willebrand Factor (vWF), a key driver of blood clotting, for the treatment of acute ischemic stroke. BB-031 is engineered to provide a rapid-onset, short-acting solution for reopening blocked arteries and is designed to be quickly neutralized in the event of bleeding complications using BB-025. This approach aims to expand the eligibility of the AIS patient population for acute revascularization by offering a safer and more effective therapy that can restore blood flow beyond the therapeutic time window of standard-of-care treatments. BB-031 is currently being evaluated in a Phase II clinical trial.
Target Audience
The primary target audience includes patients experiencing acute ischemic stroke and the medical professionals (neurologists, emergency medicine physicians) who treat them.
Features
- First-in-class RNA aptamer targeting von Willebrand Factor (vWF)
- Designed for rapid-onset and short-acting thrombolysis
- Reversible mechanism allowing quick neutralization with BB-025 in case of bleeding
- Engineered to reopen blocked arteries beyond the therapeutic time window of current treatments
- Potential to expand the eligible patient population for acute revascularization
- Being evaluated in an ongoing Phase II clinical trial (RAISE trial) for acute ischemic stroke